



CERTIFICATE OF MAILING

by certify that this paper is being deposited with the U.S. Postal Service as first class mail on the date indicated below in an envelope addressed to: Assistant Commissioner for Patents, Washington D.C. 20231.

Name of Person Mailing: Chris Myers

Signature: Chris Myers

Date: 2/28/02

TECH CENTER 160012900

MAR 12 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Supplemental Information Disclosure Statement Address to: Assistant Commissioner of Patents Washington, D.C. 20231	First Named Inventor	Nancy Krauss, et al.
	Application Number	09/844,061 ✓
	Filing Date	April 26, 2001 ✓
	Group Art Unit	1624
	Examiner	Hong Lu
	Attorney Docket No.	R0070B-REG
	Title	p-(Sulfonyl) Aryl and Heteroarylamines as Anti-Inflammatory Agents ✓

Sir:

Transmittal Letter for Supplemental Information Disclosure Statement

Applicants wish to bring to the attention of the Examiner an International Search Report, dated November 30, 2001 for the PCT patent application that is a counterpart of the subject application. The attached Information Disclosure Statement is filed in compliance with 37 CFR §1.56, and the documents cited therein may be material to the patentability of the subject patent application.

[X] Attached are:


- (a) Transmittal Letter
- (b) A copy of the PCT Search Report, dated November 30, 2001
- (c) Form 1449, "List of References Cited," with copy of each reference cited
- (d) Return postcard

[X] The Information Disclosure Statement is being submitted more than three (3) months after the filing date and after the mailing date of the first Office action on the merits, but before a final action under § 1.113 or a notice of allowance under § 1.311, whichever occurs first. The undersigned hereby certifies under 37 C.F.R. 1.97(e)(1) that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office on a counterpart foreign application not more than three (3) months prior to the filing of the Information Disclosure Statement. **Therefore, no fee is due under 37 C.F.R. 1.97(c).**

- [X] Applicants believe that no fees are due. However, should this not be the case, the Commissioner is hereby authorized to charge any additional fees that may be required to Deposit Account No. 18-1700.

The Examiner is respectfully requested to consider these documents and to make them of record in the subject application.

Respectfully submitted,



Mona Anand
Reg. No. 34,537
Attorney for Applicants

Roche Bioscience
Patent Law Dept.
3401 Hillview Avenue - M/S A2-250
Palo Alto, CA 94304
Direct Phone (650) 855-6995

February 28, 2002